Περίληψη:
Prulifloxacin, the prodrug of ulifloxacin, is a broad-spectrum
fluoroquinolone rather recently introduced in certain European
countries. We compared the antimicrobial potency of ulifloxacin with
that of other fluoroquinolones against common urinary and respiratory
bacterial pathogens. The microbial isolates were prospectively collected
between January 2007 and May 2008 from patients with community-acquired
infections in Greece. Minimum inhibitory concentrations (MICs) were
determined for ciprofloxacin, levofloxacin, moxifloxacin (for
respiratory isolates only), and ulifloxacin using the E-test method. The
binary logarithms of the MICs [log(2)(MICs)] were compared by using
the Wilcoxon signed-ranks test. A total of 409 isolates were studied.
Ulifloxacin had the lowest geometric mean MIC for the 161 Escherichia
coli, 59 Proteus mirabilis, and 22 Staphylococcus saprophyticus urinary
isolates, the second lowest geometric mean MIC for the 38 Streptococcus
pyogenes respiratory isolates (after moxifloxacin), and the third lowest
geometric mean MIC for the 114 Haemophilus influenzae and the 15
Moraxella catarrhalis respiratory isolates (after ciprofloxacin and
moxifloxacin). Compared with levofloxacin, ulifloxacin had lower
log(2)(MICs) against E. coli (p < 0.001), P. mirabilis (p < 0.001), S.
saprophyticus (p < 0.001), and S. pyogenes (p < 0.001). Compared with
ciprofloxacin, ulifloxacin had lower log(2)(MICs) against P. mirabilis
(p < 0.001), S. saprophyticus (p = 0.008), and S. pyogenes (p < 0.001),
but higher log(2)(MICs) against H. influenzae (p < 0.001) and M.
catarrhalis (p = 0.001). In comparison with other clinically relevant
fluoroquinolones, ulifloxacin had the most potent antimicrobial activity
against the community-acquired urinary isolates studied and very good
activity against the respiratory isolates.
Συγγραφείς:
Karageorgopoulos, D. E.
Maraki, S.
Vatopoulos, A. C. and
Samonis, G.
Schito, G. C.
Falagas, M. E.
